Cullinan Therapeutics, Inc. (CGEM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Cullinan Therapeutics, Inc. (CGEM) closed at USD 14.00 on 2026-10-15, a change of +82.1 % over the past year, with a market capitalization of USD 832.11M.

Cullinan Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Cullinan Therapeutics, Inc. key figures

Previous close

USD 14.00 (2026-10-15)

1-year change

+82.1 %

Market cap

USD 832.11M

Enterprise value

USD 499.64M

P/E ratio (trailing)

-4.16

P/E ratio (forward)

-5.14

EPS (trailing)

-3.11

EPS (forward)

-2.52

PEG ratio

n/a

Price to book

2.59

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.32

Employees

109

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Cullinan Therapeutics, Inc. and compare it with other stocks.